### **ICMJE DISCLOSURE FORM**

Dat	e: 25. februar 2021		
You	ır name: Søren Tang Knı	ıdsen	
Mar	nuscript title: Livstruende del	ir udløst efter pludselig ophø	r af langvarig behandling med benzodiazepiner
	nuscript number (if known		
	(	1.	
are re third comr	elated to the content of yo parties whose interests m	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ains to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
In ite	m #1 holow roport all cun	port for the work reported	d in this manuscript without time limit. For all
	r items, the time frame for	•	·
		Name all entities with whom you have this relationship or indicate none (add rows as	·
othe		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
othe	e frame: Since the initial plan	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan  All support for the present manuscript (e.g., funding, provision of study	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan  All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plane.  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim	e frame: Since the initial plane.  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim 1	e frame: Since the initial plane.  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim 1	e frame: Since the initial plane.  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) ning of the work  None	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim 1	e frame: Since the initial plan  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)  Click TAB in last row to add extra rows
Tim 1	e frame: Since the initial plane.  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months	Name all entities with whom you have this relationship or indicate none (add rows as needed)  None  None	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim 1	e frame: Since the initial plane.  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed)  None  None  None  None  AstraZeneca Novo Nordisk	Specifications/Comments (e.g., if payments were made to you or to your institution)  Click TAB in last row to add extra rows  Research grant
Tim 1	e frame: Since the initial plan  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  e frame: past 36 months  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  None  None	Specifications/Comments (e.g., if payments were made to you or to your institution)  Click TAB in last row to add extra rows  Research grant

4	Consulting fees	⊠ None		
5	Payment or honoraria for	□ None		
	lectures, presentations,	Boehringer Ingelheim	Lectures	
	speakers bureaus,	Sanofi, Mundipharma	Lectures	
	manuscript writing or educational events	Novo Nordisk, MSD	Lectures	
		AstraZeneca	Lectures	
6	Payment for expert	nt for expert 🛛 None		
	testimony	Zivone		
	,			
_	c . f !:			
7	Support for attending meetings and/or travel	None		
	meetings and/or traver	AstraZeneca		
8	Patents planned, issued or	None     Non		
	pending			
9	Participation on a Data			
	Safety Monitoring Board	Boehringer Ingelheim,	Advisory board	
	or Advisory Board	Sanofi, Mundipharma	1.60.00.7	
		Novo Nordisk, MSD	Advisory board	
10	Leadership or fiduciary	· ·		
10	role in other board,	None		
	society, committee or			
	advocacy group, paid or			
	npaid			
11	Stock or stock options	<b>⊠</b> None		
12	Receipt of equipment,	☑ None		
	materials, drugs, medical writing, gifts or other services			
	SEI VICES			
13	Other financial or non- financial interests	⊠ None		

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

# ICMJE DISCLOSURE FORM

O' Klik allor truk for at analy	o on data	
, ,		
		er pludselig ophør af langvarig behandling
nuscript number (if known	):	
elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere following questions apply to	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
author's relationships/activalins to the epidemiology of ypertensive medication, even #1 below, report all sup	hypertension, you should yen if that medication is n port for the work reported	d declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all
	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
e frame: Since the initial plan	ning of the work	
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this	⊠ None	
item.		
		Click TAB in last row to add extra rows
e frame: past 36 months		
Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3 Royalties or licenses   ☑ None		
	nuscript title: Livstranuscript number (if known e interest of transparency, elated to the content of you parties whose interests maitment to transparency arelationship/activity/interestollowing questions apply to uscript only.  Buthor's relationships/activity interestollowing questions apply to uscript only.  Buthor's relationships apply	in name: Kenneth Brandt Hansen inuscript title: Livstruende delir udløst efter inuscript number (if known):  e interest of transparency, we ask you to disclose all elated to the content of your manuscript. "Related" parties whose interests may be affected by the content interest of transparency and does not necessarily in relationship/activity/interest, it is preferable that your interest in the preferable that you following questions apply to the author's relationship uscript only.  Buthor's relationships/activities/interests should be goins to the epidemiology of hypertension, you should appertensive medication, even if that medication is not make the pidemiology of hypertension, you should appertensive medication, even if that medication is not make the processive medication in the material support for the work reporter items, the time frame for disclosure is the past 36 mone (add rows as needed)  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.  In None  Some the initial planning of the work  All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.

4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None
6	Payment for expert testimony	⊠ None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non-financial interests	None

Please place an "X" next to the following statement to indicate your agreement:

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

# ICMJE DISCLOSURE FORM

Date	e: Klik eller tryk for at angive	e en dato.	
You	r name: Vivi-Nelli Mä	ikinen	
	nuscript title: Livstr		er pludselig ophør af langvarig behandling
are re third comr list a	elated to the content of yo parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	uscript only.	·	, <u> </u>
perta antih In ite	nins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.  d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None     Non	
	No time limit for this item.		
	ttom.		Click TAB in last row to add extra rows
Time	e frame: past 36 months		CHICK TAD III IASUTOW LO AUU EXITATOWS
111116	e frame. past 50 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None     Non	
3	Royalties or licenses	None     Non	
	<b>,</b>		

4	Consulting fees	None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	⊠ None
6	Payment for expert testimony	⊠ None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non-financial interests	None

Please place an "X" next to the following statement to indicate your agreement:

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal